Bayer Pharma Aktiengesellschaft

Bayer Aktiengesellschaft

The Broad Institute, Inc.

Schering Aktiengesellschaft

Dana-farber-cancer Institute Inc.

Bayer Intellectual Property Gmbh

Piramal Imaging Sa

Detlev Sülzle

Philip Lienau

Ulf Bömer

Knut Eis

Kirstin Petersen

Ulrich Klar

Volker Schulze

Florian Puehler

Andrea Hägebarth

Ludwig Zorn

Georg Kettschau

Heidi Greulich

Lars Wortmann

Hartmut Rehwinkel

Adrian Tersteegen

Matthew Meyerson

Stefan Jaroch

Timothy A Lewis

Martin Lange

Keith Graham

Stefan Nikolaus Gradl

Dirk Kosemund

Antje Margret Wengner

Johannes Platzek

Hanns-Joachim Weinmann

Rolf Bohlmann

Volkhart Min-Jian Li

Heribert Schmitt-Willich

Thomas Frenzel

Markus Berger

Anne Mengel

Jens Ackerstaff

Hans Bauer

Christoph-Stephan Hilger

Philipp Buchgraber

Ursula Mönning

Thomas Brumby

Wilhelm Bone

Ningshu Liu

Marcus Bauser

Stefan Golz

Simon Holton

Clara Christ

Olaf Panknin

Stefan Kaulfuss

Gregor Jost

Timo Stellfeld

Stephan Siegel

Lutz Lehmann

Hubertus Pietsch

Matthias Friebe

Manuel Ellermann

Jessica Lohrke

Xiaoyun Wu

Charlotte Christine Kopitz

Margrit Hillmann

Gerardine Anne Burton

Fiona Mcdougall McDonald

Alex Burgin

Christa Hegele-Hartung

Florian Pühler

Peter Holscher

Franziska Siegel

Peter Hölscher

Julien Lefranc

Eckhard Bender

Heiko Schirmer

Dieter Moosmayer

Jens Schröder

Ulrike Rauh

Nicole Schmidt

Michael Niehues

Anja Richter

József Bálint

Bernd Radüchel

Daniel Korr

Uwe Eberspächer

Heike Schäcke

Roman Hillig

Michaela Bairlein

Steven Corsello

Daniel Basting

Anja Giese

Steven M Corsello

Christian Lechner

Bethany Kaplan

Sarah Wagner

Florian Püehler

Ananth Srinivasan

Günther Michl

Amael Madec

Adelaide Clara Faria Alvares De Lemos

Katarzyna Handing

Alisha Caliman

Hassan Youssef Harb

Jérémie Xavier G Mortier

Phi Manh Dinh

Simon Ametamey

Stephan Menz

The present invention includes name compounds of general formula (I): (I) in which R, R, Rand Rare as defined herein, methods for their preparation, pharmaceutical compositions and combinations comprising said compounds, and their use for the treatment of hyperproliferative diseases.

1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases

The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R, R, R, and R, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.

Dihydrooxadiazinones

The present invention relates to compounds of formula (I) processes for their production and their use as pharmaceuticals. The compounds are inhibitors of Casein kinase 1 alpha and/or delta (CSNK1α and/or β) useful for the treatment of proliferative disorders.

3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as CSNK1 inhibitors

The present invention provides dihydrooxydiazinone compounds of general formula (I) in which R, R, R, and R, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.

The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R, R, R, and R, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients. 

Compounds of formula (I) processes for their production and their use as pharmaceuticals. 

4H-pyrrolo[3,2-c]pyridin-4-one derivatives

The present invention relates to substituted dihydroimidazopyridinedione compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative, angiogenesis disorders, inflammatory diseases or diseases associated with inflammatory pain, as a sole agent or in combination with other active ingredients.

Substituted dihydroimidazopyridinediones as MKNK1 and MKNK2 inhibitors

The present invention relates to substituted pyrazolopyridinamine compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, inflammatory disease and disease associated with inflammatory pain, as a sole agent or in combination with other active ingredients.

Pyrazolopyridinamines as MKNK1 and MKNK2 inhibitors

The present invention relates to amido-substituted imidazopyridazine compounds of general formula (I): in which A, E, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders

The present invention relates to amido-substituted azole compounds of general formula (I), in which X, X, R, R, R, R, Rand Rare as defined in the claims which are inhibitors of TNKS1 and/or TNKS2, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. 

Amido-substituted azole compounds

The present invention relates to amino-substituted imidazopyridazine compounds of general formula (I), in which A, R1, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Aminoimidazopyridazines

The present invention relates to amino-substituted imidazopyridazine compounds of general formula (I), in which A, R1, R2, R3, R4, R5 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Amino-substituted imidazopyridazines

The present invention relates to amido-substituted imidazopyridazine compounds of general formula (I): in which A, R1, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Amidoimidazopyridazines as MKNK-1 kinase inhibitors

The present invention relates to substituted thiazolopyrimidine compounds of general formula I as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

Substituted thiazolopyrimidines

The present invention relates to amino-substituted imidazopyndazine compounds of general formula (I): in which A, R1, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Growing community of inventors

Berlin, Germany

Detlev Sülzle